If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

Shares of organ transplant innovator TransMedics Group ( TMDX -1.41%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence. TransMedics was the target of an ...

TransMedics’ stock price has dropped $9.84, or 13%, since Scorpion released a report, titled “Walk Like An Egyptian,” leveling serious allegations against the company, including fraud ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

The law firm of Kirby McInerney LLP is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the“Company”) (NASDAQ:TMDX). The investigation concerns whether TransMedics ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

Last Friday, Scorpion Capital published a 342-page short report -- yes, 342 pages! -- detailing an alleged six-month investigation into TransMedics and its business practices. TransMedics has ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.